This trial is testing a new treatment for advanced pancreatic cancer using injections and drugs to boost the immune system.
- Pancreatic Cancer Locally Advanced
2 Primary · 7 Secondary · Reporting Duration: 12 months
Awards & Highlights
1 Treatment Group
1 of 1
60 Total Participants · 1 Treatment Group
Primary Treatment: SD-101 · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the upper limit of patients engaged in this medical experiment?
"Confirmed. Evidence available on clinicaltrials.gov demonstrates that this experiment, which was first advertised on the 1st of November 2022, is still in its recruitment phase. The endeavour requires 60 participants from a single centre to be enrolled." - Anonymous Online Contributor
Are new participants being sought for this trial at the present time?
"According to clinicaltrials.gov, this medical trial is open for recruitment with the first advertisement posted on November 1st 2022 and updated as recently as November 18th of the same year." - Anonymous Online Contributor
Is SD-101 a reliable form of treatment for patients?
"Available evidence on SD-101's safety is somewhat scant, prompting our team at Power to assign it a score of 1. This early phase trial provides limited data regarding its efficacy and security." - Anonymous Online Contributor
What goals is this clinical experiment attempting to accomplish?
"The main purpose of the clinical trial, which will span 12 months, is to ascertain the maximum tolerated dose (MTD) for SD-101 administered via PRVI. Secondary objectives include assessing overall survival over a one year period and RECIST v1.1 ORR as measures of activity, coupled with determining preliminary efficacy in terms of RECIST for immune based therapeutics on clinical benefit ([CR] + [PR] + [SD])." - Anonymous Online Contributor